Trichostatin A (TSA)

目录号：S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA)是一种HDAC抑制剂，无细胞试验中IC50为1.8 nM左右。

规格 价格 库存 购买数量  
RMB 2022.93 现货
RMB 3660.93 现货
RMB 7125.3 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户购买Selleck的此次产品后发表的文献22篇：

客户使用该产品的6个实验数据：

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Trichostatin A (TSA)是一种HDAC抑制剂，无细胞试验中IC50为1.8 nM左右。
靶点
HDAC [1]
(Cell-free assay)
~1.8 nM
体外研究

Trichostatin A 抑制八种乳腺癌细胞系，包括MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3增殖，平均IC50为124.4 nM (范围为26.4-308.1 nM),作用于表达ERα的细胞系比作用于表达 ERα阴性的细胞系更有效。Trichostatin A作用于全部乳腺癌细胞系，抑制HDAC活性，平均IC50为 2.4 nM (范围为0.6-2.6 nM), 产生显著的组蛋白 H4高度乙酰化。[1]与 Trapoxin (TPX) 和 Chlamydocin 有效抑制HDAC1 或 HDAC4而不是 HDAC6不同，Trichostatin A 抑制这些HDACs，且抑制程度相似， IC50 分别为6 nM, 38 nM, 和8.6 nM。[2] Trichostatin A (100 ng/mL) 作用于MIA PaCa-2细胞，通过招募p300和 PCAF进入Sp1-NF-Y HDAC复合体，而诱导转化生长因子βⅡ型受体(TβRII) 表达，复合体与TβRII 启动子的DNA片段结合，伴随着Sp1乙酰化，且与复合体相关的HDAC数理全部降低。[4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MVjGeY5kfGmxbjDBd5NigQ>? MXuwMlfPxE1? MViyOIg> NWTs[WlS\XSqYX7vcC=> MoPL[Y5p[W6lZYOgSW5iSyCjY3X0fYxifGmxbjDhcoQhcW6lcnXhd4V{KEWQYVOgZYJ2dmSjbnPlJIlvKHSqZTD0c5RidCClZXzsJIx6e2G2ZTDhcoQh[XRidHjlJINmdGxic4Xy[oFk\Q>? NV;sNpYyOjV5OEewO|k>
TE13 NVq0T|JSTnWwY4Tpc44hSXO|YYm= MmPkNE4{|ryP NEP4O|AzPGh? NHzuWGx2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> MoGyNlU2Pzl4NkW=
TE13 NHP6[JVCeG:ydH;zbZMhSXO|YYm= Ml\aNE4{|ryP M3PuZVI1cA>? MoT0bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? Ml3sNlU2Pzl4NkW=
MEFs NYDsbXh{TnWwY4Tpc44hSXO|YYm= MVi1{txO NYr5Om52OT[q NYnMcFJncW6lcnXhd4V{KHSqZTDFVGVEKGG2dHHjbI1mdnRuIGTpdkBl\WyrdnXyfUBidmRidHjlJIVn\mmlaXXuZ5khd2ZicHXk[ZN1[WxiZn;ycYF1cW:w M4XBTVI2PDh{NkO0
SW480  NIOwOWJHfW6ldHnvckBCe3OjeR?= NVTFemJIOC5zzszN Mk\GOFhp NID0[ppFVVOR NIWwNI9z\X[ncoPld{BGVVR? M{DxUlI2PDN2OUm3
PC3  Mn[0SpVv[3Srb36gRZN{[Xl? NIrCUWYxNjIQvF2= M1K5UlQ5cA>? NGTCUmZFVVOR M1LWXZJmfmW{c3XzJGVOXA>? NHTPOoQzPTR|NEm5Oy=>
SW480  M{noT2Z2dmO2aX;uJGF{e2G7 NHPJXFkxNjIQvF2= M136W|Q5cA>? M1TG[WROW09? NYjLUG9i[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u NFPSV4QzPTR|NEm5Oy=>
PC3  M1TUfmZ2dmO2aX;uJGF{e2G7 MmDNNE4y|ryP M1fQbFQ5cA>? NUTpWmVVTE2VTx?= M{DlRYF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= NYnUSW92OjV2M{S5PVc>
SW480  NEPFS4VHfW6ldHnvckBCe3OjeR?= MofGNE4y|ryP NVi3O4E2PDiq NI\OSJVFVVOR NVq5RnFKcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= M{fJSlI2PDN2OUm3
PC3  NVTD[444TnWwY4Tpc44hSXO|YYm= MoPNNE4y|ryP NYPkOYJUPDiq MnzlSG1UVw>? MXfpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz M3m0d|I2PDN2OUm3
A431 M3qzc2Fxd3C2b4Ppd{BCe3OjeR?= NVqwOnBEOi9zMD:1NE8yODCwTR?= NVLyRY83PDiq NYS0NWhTTE2VTx?= Mm\nbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3Sq MkHONlU{PzFyNkm=
A431 MnnZSpVv[3Srb36gRZN{[Xl? M3PSVFUxdk1? NHP1R2szNzZxMUKvNlRp NEHmb3NFVVOR M{fNboFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= NVTTZplWOjV|N{GwOlk>
MDA-MB-231 M2PQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrONE03ODCwTR?= MXeyOIg> MUDEUXNQ MYTJR|UxKG:oIEGwNI5O NFnYZ4IzPTF7MkeyNS=>
MCF7 NULSPFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTzXVVGOC14MEDuUS=> NEW1cYQzPGh? MYfEUXNQ NFfQRpFKSzVyIH;mJFc2dk1? MYGyOVE6Ojd{MR?=
SKOV-3 NWLqO5FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHzeHc5OS1zMN88US=> NX\VPJV5OjSq M13KPWROW09? M3PER2lEPTBib3[gOU43|ryP Mn;qNlUyPjl2OUG=
A549 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDGNU0yOM7:TR?= M37LdFI1cA>? M4HxbGROW09? NWDPO3JVUUN3MDDv[kA{NjMQvF2= NYHERZNwOjVzNkm0PVE>
SKOV-3 M2K2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKwMlEuOc7:TR?= MnLaOFhp MXnEUXNQ MUDJR|UxKG:oIECuO:69VQ>? MXmyOVE3QTR7MR?=
A549 NGXlWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom2NE4yNTIQvF2= NUC3OlF4PDiq NXzxcoJPTE2VTx?= MmrhTWM2OCCxZjCwMlI5|ryP NEj5clQzPTF4OUS5NS=>
SKOV-3 NEm1TY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYewMlAyNTBwOd88US=> MWe3Nog> MWTEUXNQ MlOxTWM2OCCxZjCwMlMz|ryP MnLZNlUyPjl2OUG=
A549 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHU[nJMOC5yMT2wMlnPxE1? NEmwXo44Omh? MX3EUXNQ MlvyTWM2OCCxZjCwMlA3|ryP NHq3S3kzPTF4OUS5NS=>
HeLa NF:zc2FHfW6ldHnvckBCe3OjeR?= NHK3bIgzPTCwTR?= MoPNNVZp MWfEUXNQ MlG3bY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= Mo\CNlUyOTZ4OEi=
CNE2 MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqxNFAuPjBybl2= MofsNlQwPDhxN{Lo NWCzNodMcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz MoLHNlQ6Pjl7MEG=
PC3 NYDGb49RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq5NVAxNTFyMEDuUS=> MkjZNlRp MnnsTWM2OCCxZjCzNFBvVQ>? NHz1eG8zPDh3NE[1PC=>
LNCaP M1vjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e4fVExOC1zMECwcm0> MViyOIg> MmDTTWM2OCCxZjCzNFBvVQ>? NHfPSFUzPDh3NE[1PC=>
HeLa  Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OyblLPxE1? NHrpb441QGh? NF72THFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl NVz2eI1VOjR6NE[xN|U>
HMEC-1  MnKySpVv[3Srb36gRZN{[Xl? NUHZeGpYOzBybl2= MkPQNlRp NWPXTJhicW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>? NInsRVkzPDdzME[zNS=>
HeLa NF7HPWdHfW6ldHnvckBCe3OjeR?= NHvwc4kydU1? NIOzWnMxNjWq MorwZYJwdGm|aHXzJJRp\SC2b4ThcEBJTEGFIHHjeIl3cXS7 NEXzN28zPDdyN{S3OC=>
ACP02 NFTLbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HuZVI2OC9|NUCvOVAxdk1? NGfxNFczPGh? MXzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O M4S0U|I1PjZ6NUS3
ACP03 NIDWZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X5TFI2OC9|NUCvOVAxdk1? M{jhSVI1cA>? NFPzSGll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P MmrGNlQ3Pjh3NEe=
U87 GBM MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCxNFAwOzByL{WwNEBvVQ>? NWC1T|RXPzJiaB?= MVmxNFAmKGW2aHHuc4w> Mn;RdoVlfWOnczDt[YFvKGOnbHygcpVu[mW{IHL5JFMyNCB3NDygZY5lKDV6wrCl NHrmTHozPDR4NEi0NS=>
U87 GBM NY\4OXBpTnWwY4Tpc44hSXO|YYm= MWqxNFAwPTByIF7t MVW0PEBp MVKxNFAmKGW2aHHuc4w> M{PKfmlv\HWlZYOgV4Vv\XOlZX7j[U1NcWunIFHseIVz[XSrb37zJIlvKE63Y3zlZZIhVW:{cHjvcI9ogQ>? MWGyOFQ3PDh2MR?=
RPE NUjyOlZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3wXFdYOC5{L{CuOE8xNjhxMTFOwG0> NF7XWGUzPC92OD:3NkBp NVeyclFTTE2VTx?= NFTLcmtqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBjgSClZXzsJIN6[2ynIHHydoV{fA>? MYeyOFQ2PjZyMh?=
HT29  MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqxPFAhdk1? M{iwRlczKGh? MoHYTWM2OCCxZjCxPFAhdk1? NF7oS5czPDN4OEK2OS=>
hMSCs MWPGeY5kfGmxbjDBd5NigQ>? MVW2MlI2KG6P Mn;0NlQhcA>? MmmxSG1UVw>? MoTwd5Ri[mmuaYrld{BJcXO2b37lJGFk\XS7bHH0bY9vKGGwZDD0bIUhTXiycnXzd4lwdiCxZjDQcJVzcXCxdHXueEBI\W6ncx?= MV2yOFMyOjN3Nh?=
Huh7  NXXSe5pZTnWwY4Tpc44hSXO|YYm= M4qwPFAvOS9yLkWvNU4xKM7:TR?= NVPvUphCOjSq M{\W[pN2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= NUnvfFB4OjR{Nkm2O|I>
SKOV3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP0WGFiOC5yNT2yJO69VQ>? NHnXW5oyOC9{ND:0PEBp NXTqdVNKTE2VTx?= M1PtbY1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MWCyOFIzOzhyMR?=
A2780 MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOwMlA2NTJizszN MUGxNE8zPC92ODDo M{HYZ2ROW09? NFLFS|hu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MoDuNlQzOjN6MEG=
SRA01/04  NIDIWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLONE4zKM7:TR?= NELmelE1QCCq NGTD[|dFVVOR NULYdGo{e3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? MUCyOFE2Pzh5OB?=
HLEB3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojGNE4zKM7:TR?= MlTKOFghcA>? M2PyTGROW09? M1ntNpN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ NYXwZ3ZsOjRzNUe4O|g>
SRA01/04  M3[xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSwMlQwOC56IN88US=> MnSzOFghcA>? NGHzUlhFVVOR M2\Odolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2Xm[VI1OTV5OEe4
HLEB3 NVLDdnNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjmTYExNjRxMD64JO69VQ>? Mn;DOFghcA>? NIrZRXVFVVOR NYHSd5c5cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NYKwcppXOjRzNUe4O|g>
HCT116 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljONE4zKM7:TR?= NEDMe|QyOiCq Mn\r[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36= M{nEc|I1OTJ{MkOx
CA46 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPRXVQ{NzZxMUKvNlQwPDhibl2= M3rHcFQ5KGh? NUHPeIU1cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDheEAzPCCjbnSgOFghdk4EoB?= MkjBNlQxPjR7NUG=
PMNs NWLqUZRHTnWwY4Tpc44hSXO|YYm= NIm4cJc{OCCwTR?= Mn[5OFghcA>? MWnpcohq[mm2czDl[oZmem:leYTvd4l{NCCKRFHDJIFkfGm4aYT5JIFv\CCUYXOgZYN1cX[rdIm= MlXNNlM6QDh4MUe=
H1299 NHfEN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETSN4cyyqEQvF5CpC=> NFHaSpIzPC92OD:3NkBp M4TNbIV1cGGwb3y= M4TaOYlv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? NUKzNXFmOjN7MU[2NFk>
A549 NIq3eIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfnNE4zPS9yLkWvNUDPxE1? MXiyOE81QC95MjDo MYfleIhidm:u M4n3RYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NUT0OJVPOjN6Nke5PVE>
H1299 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWwMlI2NzBwNT:xJO69VQ>? MkLONlQwPDhxN{KgbC=> NUPVdm5w\XSqYX7vcC=> NHPie29qdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MlmyNlM5Pjd7OUG=
A549 MXLBdI9xfG:|aYOgRZN{[Xl? NWn4Rmo{OC53L{Gg{txO M1;NXlQ5KGh? M3;4[4V1cGGwb3y= NFLiSVRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MV6yN|g3Pzl7MR?=
H1299 Ml;FRZBweHSxc3nzJGF{e2G7 MXewMlUwOSEQvF2= NVH6O4JvPDhiaB?= NEPMWJRmfGijbn;s NFP6cmdqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3vDflI{QDZ5OUmx
SUM149PT M4jUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rNfFIwPy53L{GwJO69VQ>? MnToOFghcA>? MoPVSG1UVw>? M4LMOolv\HWlZYOgZ4VtdCCmZXH0bEBifCB{IN88UUBqdnOnboPpeIl3\Wy7 MlO0NlM4QTJ4M{i=
SUM190PT NWDtc2JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfr[Wc2OC9zMECvNlUxKG6P NYPwPINiPDhiaB?= MnvwSG1UVw>? NEjvOJpqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? M1LpS|I{Pzl{NkO4
HCT1 NYjFWHFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV2wMlIwOS5yL{WuNEDPxE1? M1u3fVEzNzJ2L{O2M|Q5KGh? NYS4PVY3cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MWqyN|c4ODByMB?=
Lovo MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnubWViOC5{L{GuNE82NjBizszN M1e5NVEzNzJ2L{O2M|Q5KGh? MUHpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NH\U[XYzOzd5MECwNC=>
AGS MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17yPFAvODF3LUGg{txO MWm3NkBp NVzRRW9wcW6mdXPld{Bk\WyuIHTlZZRpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NWH4XndEOjN5NEWwNlQ>
Huh7 M{HSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn31NUDPxE1? NYWzcW95OjRiaB?= MXnEUXNQ NGXwfWhz\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>? Mly5NlM3PDN7M{O=
ECC1 MWLGeY5kfGmxbjDBd5NigQ>? NIDLfVA2ODBibl2= NHu0SpQ2KGR? MXzEUXNQ M4Lkb4lv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF Mme0NlM2OzB5Nkm=
HEC1A NHLWRndHfW6ldHnvckBCe3OjeR?= Mk\QOVAxKG6P MX:1JIQ> M4Hq[GROW09? MnjIbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? M33MW|I{PTNyN{[5
EN1 MYfGeY5kfGmxbjDBd5NigQ>? NV;jb4hrPTByIH7N MkP0OUBl NHTjTHdFVVOR MVvpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MUeyN|U{ODd4OR?=
MFE296 M4S2R2Z2dmO2aX;uJGF{e2G7 MmTFOVAxKG6P NIDUXGI2KGR? NWToemo1TE2VTx?= NUT1W5BtcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= M4LlcFI{PTNyN{[5
HASMCs NV3qV2ZZTnWwY4Tpc44hSXO|YYm= MoX6NE02ODBibl2= NUPM[WhlPiCm NHnlZlRld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDIRWREKGGwZDDj[YxtKH[rYXLpcIl1gQ>? MXGyN|UyQDR4Nx?=
U373 MYXGeY5kfGmxbjDBd5NigQ>? NVLleGxpOC5{NT:wMlUwOSEQvF2= NUCydoNHOjRiaB?= MYTpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? M2PqVFI{PDd2MUex
ARN8  MlvSSpVv[3Srb36gRZN{[Xl? NH3xWo4xNjB3LUKg{txO NWHoRpFwOjRiaB?= MWDy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> NGrxepgzOzR5MEW0NC=>
MCF7 M2q2XGZ2dmO2aX;uJGF{e2G7 NWHF[lBIOC5yNT2yJO69VQ>? Mme5NlQhcA>? MlLFdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> MWOyN|Q4ODV2MB?=
H1299  NEPxeHdHfW6ldHnvckBCe3OjeR?= Mke4NE4{O+LCk{JCpOK2VQ>? M4\WTVI1NzR6IHi= MYTEUXNQ NXLydI9FcW6lcnXhd4V{KEVvY3HkbIVzcW5icILveIVqdiCuZY\lcJMh\G:|ZTDk[ZBmdmSnboTsfS=> M2nhVlI{PDZzOUe1
H1299 MVnGeY5kfGmxbjDBd5NigQ>? NUTQV4pQOC53IN88US=> M1HvfVQ5KGh? NXX3U3dxTE2VTx?= MYXpcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu M2\0NFI{PDZzOUe1
H1299 NXy1PG5NTnWwY4Tpc44hSXO|YYm= NIH0XHIxNjVizszN MknqOFghcA>? NYLnUWxUTE2VTx?= MnfPbY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW|c9MgJINwdWKrbnWge4l1cCC|aXzpZolvcW5? M2nsXVI{PDZzOUe1
MG-63  NXzp[WtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWwMlMh|ryP MmrpNVIuQTZiaB?= M{DzNWROW09? NWXhN3I3cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> NF6wbpMzOzR3MUixOy=>
LM8 M3;OfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LrbVAvOyEQvF2= M{XUb|EzNTl4IHi= Mn7KSG1UVw>? NWjZd49ycW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> MWqyN|Q2OThzNx?=
K562 NYrYPJhqTnWwY4Tpc44hSXO|YYm= M1jpNVAvPSEQvF2= MVWyOEBp NHrnXllmfGijbn;s MnLI[IVkemWjc3XzJJRp\SCnbor5cYUh[WO2aY\peJkhd2ZiSFTBR5Mh[29vdILlZZRu\W62IIfpeIgh[3W{Y4XtbY4> MX[yN|Q{ODl3Nx?=
HEL MljBSpVv[3Srb36gRZN{[Xl? Mn7NNE42KM7:TR?= MVSyOEBp MVPleIhidm:u NXnFVXF[\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? NHT5fGszOzR|MEm1Oy=>
HL60 MWnBdI9xfG:|aYOgRZN{[Xl? M1i5XVEh|ryP MkP3NlQhcA>? MoHKbY5lfWOnc9MgZ4VtdCCmZXH0bC=> MVKyN|QxODVzOR?=
KG1 Mn3MRZBweHSxc3nzJGF{e2G7 MUCxJO69VQ>? NITIdYEzPCCq NUO3bItqcW6mdXPld:Kh[2WubDDk[YF1cA>? M4PYU|I{PDByNUG5
Kazumi MVvBdI9xfG:|aYOgRZN{[Xl? MYWxJO69VQ>? NID5NFgzPCCq MlPybY5lfWOnc9MgZ4VtdCCmZXH0bC=> NUfDN2VVOjN2MEC1NVk>
K562 M2DZfmFxd3C2b4Ppd{BCe3OjeR?= M2TDNlEh|ryP M3TNZVI1KGh? M{fLVIlv\HWlZYRCpINmdGxiZHXheIg> MmjKNlM1ODB3MUm=
THP1 NGnHRlZCeG:ydH;zbZMhSXO|YYm= M164SVEh|ryP MlzHNlQhcA>? MnrGbY5lfWOnc9MgZ4VtdCCmZXH0bC=> M3;uNlI{PDByNUG5
SH-SY5Y MmD4SpVv[3Srb36gRZN{[Xl? MmHHNlUxKG6P NWjzNFU2OTZiaB?= MkG4Z4hidmenczDlfJBz\XO|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m|LDD1dJRic2ViYX7kJIVn\my3eB?= MkXKNlM{OjZ2MkK=
HEK293 NE\QNZJHfW6ldHnvckBCe3OjeR?= MWixJOK2VcLi M3zxTlE5KGkEoB?= Mn7vbY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? M3jiNFI{Ojh2OES4
HTK NWDsVlhFTnWwY4Tpc44hSXO|YYm= MWq0NFAhdk1? MVq3NkBp NGnOSplqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v MUCyN|I5PDByMh?=
HTK MX3GeY5kfGmxbjDBd5NigQ>? NUfWWoFKOTByLUiwNI5O NITqT2c4OiCq MVzicI9kc3NiVFfGMe6z6oDVSX7keYNm\CCUT2OgZY5lKEh{T{NCpGFk[3WvdXzheIlwdg>? MXmyN|I5PDByMh?=
Caco-2  MnHMSpVv[3Srb36gRZN{[Xl? MYqxJOK2VcLi NHvFXIczPCCq MYPk[YNz\WG|ZYOgV2VTXCCycn;0[YlvKGW6cILld5Nqd25? M1rNd|I{OTl3MEew
HeLa NYju[WMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\lb5QyODBibl2= NETZXm8zPCCq NY\2cZJ7TE2VTx?= M2\xOmlEPTBib3[gNVAxdk1? NFLiV3AzOzF4NUe0PC=>
HeLa M33GeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K1NVQxKG6P NUT5dXE6PDhiaB?= NVmwdHd{TE2VTx?= NUP2WYhTUUN3MDDv[kA1OG6P M{PrcFI{OTZ3N{S4
HeLa MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHiNYo2OjBibl2= M17IOVczKGh? NXXIZYhyTE2VTx?= NHzHNnpKSzVyIH;mJFIxdk1? M1;pcVI{OTZ3N{S4
HeLa NFnJVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[xNE8{OC93MDDuUS=> NGfEU4M4OiCq MkTZSG1UVw>? M3XmWIlv[3KnYYPld{B1cGViboXtZoVzKG:oIF3NVEAp|pUQqH2pJIxwe3NiY3XscJMh\G:|ZTDk[ZBmdmSnboTsfS=> MXiyN|E3PTd2OB?=
MDA-MB-231 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCyOU01ODBibl2= M3njflQ5KGh? Mn;4TWM2OCCxZjCyOlMvOm6PwrC= NY\SU|ZKOjNyNUWxPVg>
MCF-7  MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r0N|I2NTRyMDDuUS=> NG[4VYs1QCCq M4XtPGlEPTBib3[gNlIxNjSwTR?= MWGyN|A2PTF7OB?=
ECC-1  MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPh[VMyODBibl2= MorBNlQhcA>? NGDJcmRmfGijbn;s MlrSbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn MV2yN|AzQDhyMx?=
HEC-1A NWr1elN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLaemFFOTByIH7N MlvGNlQhcA>? M1vJdYV1cGGwb3y= MlK0bY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzln MnixNlMxOjh6MEO=
NHAC-kn M1;Qcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmxNE8yODBxNUCwJI5O M2jSVlEzKGh? M4[x[mROW09? MX7JR|UxKG:oIEWwNI5O MVSyN|AyPzh5MR?=
A549 NGTHc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzNOXIzPTBibl2= NIfnXlI3NTd{IHi= M37hdWROW09? MUnjZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni M4m0XFIzQTl2N{iw
MG-63 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:wN|AxKG6P NX3BTFZTOTJiaB?= M2DGeWROW09? MYnpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gPFYm M{LPR|IzPzl7M{O4
MG-63 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKzNFAhdk1? M3fNbFI1KGh? MonkSG1UVw>? NV:zN|VwcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDZ5JR?= MYqyNlc6QTN|OB?=
MG-63 Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG0N|AxKG6P MV[0PEBp MmT2SG1UVw>? NX\ZXG5ScW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDV4JR?= M3HNRVIzPzl7M{O4
HL60  M2D3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn0U2EyPTBvM{WwJI5O NXjjPIJUOjRiaB?= Mk\ZbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> NEL5XHUzOjd3M{ezPS=>
U937 NILtSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzBNVUxNTN3MDDuUS=> MmnhNlQhcA>? M4PjfYlv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> MV6yNlc2Ozd|OR?=
SCC-6 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LVeFIxOC1|MkCwJI5O Mn\SNVIwOjRxNEigbC=> MWTEUXNQ NXHLcplGcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MYqyNlU2OjN{MR?=
U87  MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\OWpIyODBvM{CwJI5o NUC1emFOOjRiaB?= NXHrW|JzcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne= MlTGNlIzPzB6NEm=
K562 NXXUN|FPTnWwY4Tpc44hSXO|YYm= MXqxJO69VQ>? MmrXNVIhcA>? NVW2W2NWTE2VTx?= M4S1cYVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS NFe4cowzOjF5OUG5PC=>
Reh NX\nVohPTnWwY4Tpc44hSXO|YYm= M1viWFAvOy9zIN88US=> M4W3R|EzKGh? NUHGeWJDTE2VTx?= Mlfa[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= M{LvNlIzOTd7MUm4

... Click to View More Cell Line Experimental Data
体内研究 Administration of Trichostatin A 按 0.5 mg/kg 剂量处理N-甲基-N-亚硝基脲致癌物诱发的大鼠乳腺癌模型，持续处理4周，具有有效的抗癌活性，即使按按高达5 mg/kg剂量处理也没有任何可测量到的毒性。[1]Trichostatin A 按10 mg/kg 剂量单独腹腔注射给药非转基因和脊髓性肌萎缩症（SMA）模型鼠，导致乙酰化的 H3 和 H4组蛋白水平提高，也导致活运动神经元(SMN) 基因表达稍微提高。Trichostatin A 每天按10 mg/kg剂量处理SMA模型鼠，促进存活, 减轻体重下降,且增强运动行为。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[1]
+ 展开

体外HDAC活性 :

从每种乳腺癌细胞系(MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51,或 SK-BR-3)中准备全部细胞提取物。在溶于0.1% (v/v)乙醇的不同浓度Trichostatin A存在时，或者使用0.1% (v/v)乙醇作为对照, 20 μL 细胞粗提取物(~2.5 ×105 个细胞)与 1 μL ~1.5 × 106 cpm [3H]乙酰标记的组蛋白 H4 肽底物(第2-20位NH2-末端残基) 在25oC下温育60分钟。使用50 μL 1 M HCl/0.16 M 乙酸对每组 200-μL 反应进行淬火，然后使用600 μL 乙酸乙酯进行抽提，通过闪烁计数器测量释放的[3H]乙酸。使用非线性回归曲线拟合抑制数据，绘制合适的剂量反应曲线，而测定IC50。
细胞实验：[1]
+ 展开
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3
  • Concentrations: 溶于无水酒精,终浓度为~10 μM
  • Incubation Time: 96小时
  • Method: 使用不同浓度Trichostatin A处理细胞96小时。处理后,使用sulforhodamine B 比色分析测定细胞增殖。通过台酚蓝染色排除法测定细胞活力。
    (Only for Reference)
动物实验：[1]
+ 展开
  • Animal Models: 携带NMU诱导的肿瘤的近交系(Ludwig/Wistar/Olac)处女鼠
  • Formulation: 溶于DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: 皮下注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
2% DMSO+30% PEG 300+2% Tween 80+ddH2O 		3mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 302.4
化学式

C17H22N2O3
CAS号 58880-19-6
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03185429 Not yet recruiting Tumor Gastric|Tumor Colorectal BGI China|Fujian Cancer Hospital December 2017 Not Applicable
NCT02959905 Recruiting Metastatic Melanoma BGI China|Sun Yat-sen University December 2016 Phase 1
NCT02695758 Completed Osteoarthritis: Shoulder Rothman Institute Orthopaedics December 2014 Not Applicable
NCT00158418 Completed Osteoarthritis Fowler Kennedy Sport Medicine Clinic|Zimmer Biomet August 2002 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答：

    Our S1045 Trichostatin A (TSA) is R enantiomer.

Selleck产品目录册

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

  • LMK-235 New

    LMK-235是HDAC4和HDAC5的选择性抑制剂， IC50分别为11.9 nM 和 4.2 nM。

  • CAY10603 New

    CAY10603是一种强效的选择性HDAC6抑制剂，IC50为2 pM，选择性比其它HDACs高200多倍。

  • 4SC-202 New

    4SC-202是一种选择性的I类HDAC抑制剂，对HDAC1，HDAC2，和HDAC3的IC50分别为1.20 μM，1.12 μM，和0.57 μM。也对Lysine specific demethylase 1 (LSD1)表现出抑制活性。Phase 1。

  • Panobinostat (LBH589)

    Panobinostat (LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Phase 3。

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA)是一种HDAC抑制剂，无细胞试验中IC50为~10 nM。

    Features:Vorinostat是广谱HDAC活性抑制剂，抑制I和II类酶 。

  • Entinostat (MS-275)

    Entinostat (MS-275)强烈抑制HDAC1和HDAC3，无细胞试验中IC50分别为0.51 μM和1.7 μM，抑制作用强于HDACs 4， 6， 8，和10。Phase 3。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1和HDAC2抑制剂，无细胞试验中IC50分别为36 nM和47 nM。

    Features:Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。

  • RGFP966

    RGFP966是一种HDAC3抑制剂，无细胞试验中IC50为0.08μM ，比作用于其他HDAC选择性高200倍以上。

  • Tubastatin A

    Tubastatin A是一种有效的，选择性HDAC6抑制剂，无细胞试验中IC50为15 nM，选择性远高于所有其他同工酶(1000倍)除了HDAC8(57倍)。

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103)是一种有效的HDAC抑制剂，对HDAC1抑制作用最强，无细胞试验中IC50为0.15 μM，比作用于HDAC2， 3，和11选择性高2到10倍，对HDAC4， 5， 6， 7，和8没有抑制活性。Phase 2。

Tags: 购买Trichostatin A (TSA) | Trichostatin A (TSA)供应商 | 采购Trichostatin A (TSA) | Trichostatin A (TSA)价格 | Trichostatin A (TSA)生产 | 订购Trichostatin A (TSA) | Trichostatin A (TSA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID